Tag
Strong wave of innovation and new Biologic therapies resulting in high demands Building flexible global capacities at various scales and multiple global locations to ensure reliable supplies and serve patients’ needs worldwide Business continuity planning, crisis management, pandemic preparedness & implementation of additional specific protection measures Close collaboration, intensive and solution-oriented exchange with customers and partners to ensure global patient supplies Managing diverse and complex challenges through digital transformation Critical success factor: Operational excellence, capacity & capabilities expansion and our peoples dedication — Uwe Buecheler Corporate SVP Biopharmaceuticals Boehringer Ingelheim Uwe Buecheler, Ph. D. joint Boehringer Ingelheim (formerly Dr. Karl…
Continue reading How biomanufacturing can address the dichotomy of small volume precision medicines and high volume blockbuster drugs Building flexible global manufacturing networks to meet our industry’s evolving needs Leveraging cutting edge innovation to maximize process intensification and augment flexibility Creating high performance teams and building and maintaining a culture of quality, reliability and innovation as key differentiator and foundation for continued success Please note: Q&A appears in this separate video: — Jens Vogel President & CEO, BI Fremont Inc. Boehringer Ingelheim Biopharmaceuticals GmbH Dr. Jens Vogel is President and CEO of Boehringer Ingelheim Fremont Inc., the US arm of Boehringer…
Continue readingDebating the merits of nimble and flexible facilities versus manufacturing battleships Preparing your pilot plants and manufacturing facilities to move forward with Phase II-III approvals Forecasting requirements for optimizing manufacturing equipment, facilities and partners to increase speed to market Achieving business goals to better manage times of product and economic uncertainty Putting theory into practice: Implementing key metrics to improve manufacturing flexibility — Uwe Buecheler Corporate SVP, Biopharmaceuticals Boehringer Ingelheim Uwe Buecheler, joint Boehringer Ingelheim (formerly Dr. Karl Thomae GmbH) in 1991. During his time at Boehringer Ingelheim he held different positions in Biopharmaceuticals in Regulatory Affairs, Biological Safety and…
Continue reading